Hypertension denials in California external review
In the California DMHC record, independent physician reviewers decided 126 published external-review cases involving hypertensionand overturned the plan’s denial in 42.9%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for hypertension
| Category | Decisions | Overturned |
|---|---|---|
| Zepbound | 9 | 66.7% |
| Advanced Lipoprotein Testing | 8 | 0% |
| Wegovy | 5 | 100% |
| Lap-band Surgery | 4 | 50% |
| Roux-en-y Gastric Bypass | 4 | 75% |
| Crestor | 3 | 0% |
| Laparoscopic Sleeve Gastrectomy | 3 | 66.7% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 100 | 50% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 25 | 12% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Zepbound auto-injector. Increased weight is detrimental to overall health and wellbeing. Researchers report a significant increase in the risk for early acute myocardial infarction (AMI) and ischemic stroke (IS) and note that cardiovascular disease (CVD) death was noticeable in overweight young women, with a marked increase in obese women. The U.S.
Nature of Statutory Criteria/Case Summary: The patient has been diagnosed with hypertension, dyslipidemia, and atherosclerotic heart disease. The records noted a history of percutaneous coronary intervention. The patient was noted to have experienced left-sided chest tightness associated with weakness and shortness of breath in 2006. The patient subsequently underwent cardiac stent placement. The patient was noted to have undergone a second cardiac stenting procedure. A myocardial perfusion study revealed normal left ventricular perfusion. The patient’s blood pressure was noted to be 146/90. The provider discontinued Azor and prescribed Edarbyclor and amlodipine. The patient denied chest pain, shortness of breath, and palpitations. The patient’s blood pressure was noted to be 140/100. Samples of Edarbyclor were provided to the patient.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for Zepbound. According to the American Association of Clinical Endocrinologists (AACE) guidelines, patients with overweight or obesity “should be considered for treatment with a weight-loss medication combined with lifestyle therapy when necessary” (Garvey, et al.). The Endocrine Society guidelines have similar recommendations and specifically state that “Patients who have a history of being unable to successfully lose and maintain weight and who meet label indications are candidates for weight loss medications”.
Physician 1: The patient is a 50-year-old male who was recently evaluated for alcoholic cardiomyopathy. His cardiac workup revealed a normal electrocardiogram (EKG) and an impedance cardiography (ICG), which was positive for hypertension. The Health Plan has denied reimbursement for the ICG on the basis that it is considered investigational for evaluation of hypertension.The patient has hypertension JNC stage III, treated with one medication, Toprol XL-50 mgm. Review of the relevant scientific data reveals that there is no body of peer-reviewed literature to substantiate the effectiveness of ICG in the management of hypertension. The use of ICG in this clinical setting was without clinical value and was unnecessary.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving hypertension, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY